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A b s t r A c t
Many factors appear to influence the chance of acquiring Clostridium difficile (c. difficile) 
infection, and an accurate identification of risk factors could be beneficial in many ways. 
thus, in the present study, clinical risk factors for c. difficile-associated disease (cDAD) 
in Korea were identified. A total of 93 patients who met the inclusion criteria and 186 
age/gender/ward/admission period-matched control patients were included in this study. 
statistically significant associations were found with presence of chronic lung diseases 
(odds ratio [or], 3.41; 95% confidence interval [ci], 1.25-9.32; p = 0.017), presence of 
ileus (or, 10.05; 95% ci, 2.42-41.80; p = 0.001), presence of intensive care unit (icU) stay 
(or, 9.79; 95% ci, 3.03-31.68; p < 0.001), use of cephalosphorins (or, 3.30; 95% ci, 1.13-9.62; 
p = 0.029), history of surgery (or, 10.89; 95% ci, 3.96-29.92; p < 0.001), and history of long-
term care facility stay (or, 14.90; 95% ci, 4.02-55.26; p < 0.001). Awareness of cDAD is 
critical to provide appropriate clinical care. surveillance of the national incidence rate 
and multicenter studies are needed, and the potential value of a c. difficile vaccine should 
be studied.
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Introduction
Clostridium difficile-associated disease (cDAD) has been clearly 
associated with the use of broad-spectrum antimicrobial 
agents worldwide. Clostridium difficile (C. difficile) is a gram-
positive, anaerobic, spore-forming bacillus. the clinical 
manifestations of cDAD range from asymptomatic colonization 
of the gastrointestinal tract and mild diarrhea to diarrhea 
with colitis, which can progress to toxic dilatation, sepsis, 
perforation, and death.1 Although cDAD may occur during or 
following the administration of any antimicrobial agent, higher 
rates are more commonly associated with cephalosporins, 
ampicillin/amoxicillin, fluoroquinolones, and clindamycin.1-6 
in addition to antimicrobial exposure, other variables that 
may contribute to cDAD include use of chemotherapeutic 
agents, severe underlying illness, history of gastrointestinal 
surgery, advanced patient age, use of enteral tube feedings, 
and exposure to C. difficile.7-14
Many factors appear to influence the chance of acquiring 
C. difficile infection, and an accurate identification of risk factors 
could be beneficial in many ways. However, information about 
cDAD is scarce in Korea. A full analysis of potential risk factors 
was warranted. thus, in this study, the clinical risk factors for 
cDAD in Korea were identified.
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Methods
the Eulji Medical center is a 1,030-bed tertiary care teaching 
hospital. A case patient was defined as any patient who 
had a positive fecal C. difficile toxin (cDt) A by enzyme 
immunosorbent toxin A assay (cDA 2) result between January 
2006 and May 2010. for each case patient, two control patients 
were randomly selected from a pool of all of the age/gender/
ward/admission period-matched patients. the data were 
gathered by a retrospective chart review, which included 
patient demographics; comorbidities (cardiovascular diseases, 
chronic lung diseases, diabetes mellitus, renal failure, or 
malignancy); presence of ileus or intensive care unit (icU) 
stay within 30 days of cDAD diagnosis; use of proton pump 
inhibitor (PPi), H2 blocker, cephalosporins, carbapenems, 
aminoglycosides, macrolides, or quinolones within 30 days of 
cDAD diagnosis; and history of prior hospitalization, long-term 
care facility stay, surgery, or previous cDAD within 30 days of 
diagnosis of cDAD. the laboratory data were collected over a 
seven-day period spanning four days before and two days 
after the day of submission of the first C. difficile-positive fecal 
specimen. this interval was chosen to account for variability 
in the promptness of C. difficile testing and initiation of 
treatment among healthcare providers; max leukocyte count 
(> 20,000/uL), max serum glucose (> 150 mg/dL), max creatinine 
level (> 2 mg/dL), alanine aminotranferase levels (> 40 iU/L), 
and minimum serum albumin level (< 2.5 g/dL).
the data generated were coded, entered, validated and 
analyzed using the statistical Package for social science (sPss 
inc. – chicago, UsA), version 18.0. relative risks (rr), both 
univariate and multivariate together with 95% confidence 
interval (ci) were calculated. in multivariate analysis, risk 
factors that had a p-value < 0.05 in univariate analysis were 
included, as well as other factors that were known to be 
associated with seroconversion.
Results
A total of 93 patients who met the aforementioned criteria 
and 186 age/gender/ward/admission period-matched control 
patients were included in this study. the mean ages of 
case/control patients were 63.0 ± 16.5 and 62.3 ± 16.9 years, 
respectively. the gender ratios (M/f) of case/control patients 
were 37/56 and 74/112, respectively. the incidence rate of 
cDAD during this study period was 0.2%. Univariate analysis 
showed that the case patients were more likely than the 
control patients to have chronic lung diseases (29.0% vs. 
9.1%); presence of ileus (14.0% vs. 2.2%); presence of icU stay 
(28.0% vs. 3.2%); use of H2 blocker (63.4% vs. 81.2%); use of 
cephalosphorins (39.8% vs. 9.1%), aminoglycosides (9.7% vs. 
1.6%), and macrolides (11.8% vs. 1.6%); non-use of quinolones 
(28% vs. 73.7%); history of prior hospitalization (67.7% vs. 46.8%); 
history of long-term care facility stay (24.7% vs. 2.7%); history 
of surgery (37.6% vs. 5.4%); history of previous cDAD (10.8% 
vs. 1.1%); and presence of hypoalbuminemia (17.2% vs. 6.5%) 
(table 1). factors demonstrating an association with cDAD 
by univariate analyses and other factors that were known 
to be associated with cDAD were evaluated in a multiple 
logistic regression model (table 2). statistically significant 
associations were found with the presence of chronic lung 
diseases (odds ratio [or], 3.41; 95% ci, 1.25-9.32; p = 0.017), the 
presence of ileus (or, 10.05; 95% ci, 2.42-41.80; p = 0.001), 
the presence of icU stay (or, 9.79; 95% ci, 3.03-31.68; 
p < 0.001), the use of cephalosphorins (or, 3.30; 95% ci, 1.13-9.62; 
p = 0.029), the history of surgery (or, 10.89; 95% ci, 3.96-29.92; 
p < 0.001), and the history of long-term care facility stay 
(or, 14.90; 95% ci, 4.02-55.26; p < 0.001). the use of H2 
blocker showed a protective effect to cDAD (or, 0.30; 95% ci, 
0.13-0.69; p = 0.005). Among surgeries, orthopedic surgery had 
the greatest risk, followed by neurosurgery and gastrointestinal 
surgery. 
Discussion
C. difficile infection is the most common cause of hospital-
acquired diarrhea, accounting for 30% of patients with 
antibiotic-associated diarrhea, 70% of those with antibiotic-
associated colitis, and most cases of pseudomembranous 
colitis. in addition, healthy adults have been shown to 
be colonized with C. difficile, and outpatient detection rate in 
specimens has been reported as high as 10.7%.15,16 Although 
the incidence rate in Korea was low (0.2-0.7%) compared to the 
United states (30-50%) or to Europe (40-60%), there was 
notable recent increase of incidence, which is reasoned as the 
increased diagnostic approach of cDt assay.17
two likely mechanistic factors increasing the risk of 
recurrent cDi are an inadequate immune response to 
C. difficile toxins and persistent disruption of the normal 
colonic flora.18
the present study demonstrated that patients with chronic 
lung disease had higher risk of cDAD. Underlying illness 
has been hypothesized to decrease host immunity, thereby 
increasing susceptibility to this disease process. in addition, 
patients with chronic lung disease often experience higher 
rates of pneumonia, so they have a higher chance of exposure 
to antibiotics than healthy adults, rendering chronic lung 
diseases as a risk factor of cDAD.  
increased antibiotic coverage could lead to further 
suppression of the normal bowel flora, creating an optimal 
environment for C. difficile to thrive. interestingly, duration of 
antibiotic use was not found to be significant. this suggests 
that broad coverage rather than duration of use contributes 
to bacterial inhibition in the gut.19 cephalospirins had the 
highest ratio among antibiotics causative of cDi.17 Although 
treatment of community-acquired pneumonia (cAP) with 
newer fluoroquinolones may contribute to selection for 
C. difficile, fluoroquinolones were not associated with increased 
acquisition rates for C. difficile.20 Many of the fluoroquinolone-
associated adverse effects and toxicities occur more frequently 
in patients with pre-existing risk factors. the risk of developing 
cDi was higher in patients receiving a combination of a 
cephalosporin and fluoroquinolone.21 the present study 
revealed that only the use of cephalosporins increased cDAD. 
it is estimated that 15-20% of patients experience cDi 
recurrence.15 relapse of cDAD is usually caused by the 
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 Case group 
(n = 93)
Control group  
(n = 186)
p-value 
Age, years 63.0 ± 16.5 62.3 ± 16.9 ns
Gender, M/f 37/56 74/112 ns
comorbidities
 cardiovascular diseases 39 (41.9) 76 (40.9) ns
 chronic lung diseases 27 (29.0) 17 (9.1) < 0.001
 Diabetes mellitus 23 (24.7) 33 (17.7) ns
 renal failure 9 (9.7) 4 (2.2) ns
 Malignancy 17 (18.3) 20 (10.8) ns
Presence of
 ileus 13 (14.0) 4 (2.2) < 0.001
 icU stay 26 (28.0) 6 (3.2) < 0.001
Use of
 PPi 14 (15.1) 26 (14.0) ns
 H2 blocker 59 (63.4) 151 (81.2) 0.002
 cephalosporins 37 (39.8) 17 (9.1) < 0.001
 carbapenems 13 (14.0) 8 (4.3) ns
 Aminoglycosides 9 (9.7) 3 (1.6) 0.003
 Macrolides 11 (11.8) 3 (1.6) 0.001
 Quinolones 26 (28.0) 137 (73.7) < 0.001
History of
 Prior hospitalization 63 (67.7) 87 (46.8) 0.001
 Long-term care facility stay 23 (24.7) 5 (2.7) < 0.001
 operation 35 (37.6) 10 (5.4) < 0.001
  Previous cDAD 10 (10.8) 2 (1.1) < 0.001
 Glucose > 150 mg/dL 18 (19.4) 40 (21.5) ns
 Wbc count > 20 x 103/mm3 10 (10.8) 13 (7.0) ns
 ALt > 40 iU 15 (16.1) 16 (8.6) ns
 cr > 2.0 mg/dL 7 (7.5) 7 (3.8) ns
 Albumin < 2.5 mg/dL 16 (17.2) 12 (6.5) 0.010
icU, intensive care unit; PPi, proton pump inhibitor; cDAD, Clostridium difficile-associated diarrhea; Wbc, white blood cell; ALt, alanine 
transferase; cr, creatinine; sD, standard deviation.
Risk factor Adjusted OR 95% CI p-value
chronic lung diseases 3.41 1.25-9.32 0.017
Presence of ileus 10.05 2.42-41.80 0.001
Presence of icU stay 9.79 3.03-31.68 < 0.001
Use of H2 blocker 0.30 0.13-0.69 0.005
Use of cephalosphorins 3.30 1.13-9.62 0.029
History of operation 10.89 3.96-29.92 < 0.001
History of long-term care facility stay 14.90 4.02-55.26 < 0.001
icU, intensive care unit; or, odds ratio.
Table 1 - Univariate analysis of risk factors for Clostridium difficile-associated diseases (mean ± SD)
Table 2 - Multivariate analysis of risk factors for Clostridium difficile-associated diseases
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original strain, and the etiology is multifactorial. important 
epidemiologic risk factors include advanced age, continuation 
of other antibiotics, and prolonged hospital stays.18 Patients 
with recent cephalosporin use, cDi on admission, and transfer 
from another hospital were more likely to fail metronidazole 
and may benefit from early aggressive therapy. infection 
with the epidemic nAP-1 strain was not associated with 
metronidazole failure in endemic cDi.22 continued use of 
non-C. difficile antibiotics after diagnosis of cDi, concomitant 
prescription of antacid medications, and older age were 
significantly associated with increased risk of recurrent cDi.15 
Evidence for the association between C. difficile and the use of 
PPis is unclear. Whether or not antacids increase the risk 
of cDi is controversial, with negative and positive reports of 
antacids as risk factors. in theory, the decreased gastric acid 
associated with antacid use increases the risk for transit of 
C. difficile vegetative cells and spores to pass beyond the 
stomach and cause infection. it is thought that PPis are more 
important risk factors than other anti-secretory agents.15 
this study, unlike previous reports, did not find PPis to be a 
significant factor for cDAD, which is still controversial.
cDAD is also a recognized postoperative complication,19 
especially after total joint arthroplasty (tJA). in hospitalized 
patients, recent reports have observed a 30% increase in cDAD 
from 1984-1994 to 1994-2000, and a 3.5% to 15.3% increase in 
mortality from this complication during the same period.19 
the literature specific to cDAD in orthopedic patients is very 
limited. in the late 1980s and early 1990s, the discovery of the 
association between prophylactic antibiotic use and cDAD 
contributed to the universal recommendation of no more than 
three doses of prophylactic antibiotics before surgery.19 the 
study by Kurd et al. suggests that patients with deteriorated 
physical status (AsA score, hospital duration), or those who 
receive more than one antibiotic after surgery are at a higher 
risk for developing cDAD after tJA.19 in the present study, the 
patients who had a history of surgery had higher risk of cDAD. 
Among the surgeries, orthopedic surgery was the highest, 
followed by neurosurgery and gastrointestinal surgery. it is 
reasoned that the high rate of postoperative antibiotics use was 
the culprit. the most significant risk factor in surgical patients 
is the routine use of perioperative prophylactic antibiotics. 
Additionally, it is postulated that the postoperative population 
is more exposed to highly virulent hospital-acquired strains, 
and may be more immunosuppressed than typical patients. 
severe cDAD was associated with age > 70 years, maximum 
leukocyte count > 20,000 cells/mL, minimum albumin 
level < 2.5 g/dL, maximum creatinine level > 2 mg/dL, small 
bowel obstruction or ileus, and computed tomography scan 
showing colorectal inflammation.23 Hypoalbuminemia and 
elevated serum urea levels were independently associated 
with mortality.24 the present study demonstrated that 
hypoalbuminemia increased the tendency for cDAD. the 
organism has evolved over the last eight years to become more 
virulent and resistant to antimicrobials (nAP1/027 strain), 
causing a more severe form of the disease that has increased 
mortality and healthcare costs. the nAP-1 strain (also referred 
as ribotype 027, toxinotype iii, or restriction endocuclease 
analysis group bi, depending on the typing method used) has 
since been found to carry certain virulence determinants that 
could contribute to an increase in disease severity. nAP-1 
isolates from Quebec were found to produce 16 and 23 times 
as much toxin A and toxin b in vitro, respectively, as compared 
with historic non-nAP-1 isolates (toxinotype 0) of C. difficile. this 
increase in toxin production is thought to be due to deletion 
mutations of the tcd gene in the toxin production. the nAP-1 
strain also produces a separate, third toxin named binary toxin, 
homologous to the iota toxin in C. perfringens. However, the role, 
if any, played by binary toxin in inducing severe cDi is currently 
unclear.25 the b1/nAP/027 strain resistance to quinolone 
is important to the spread of this organism.17 in Korea, this 
organism was first found in 2009. in addition, the incidence of 
tcdA-tcdb+ has increased from under 7% in 2002 to 27.0% in 
2005. therefore, the test should include both toxin A and b.17
current guidelines recommend that the first recurrent episode 
should be treated with the same agent (i.e. metronidazole or 
vancomycin) used for the index episode. However, if the first 
recurrence is characterized as severe, vancomycin should 
be used. A reasonable strategy for managing a subsequent 
episode involves tapering followed by pulsed doses of 
vancomycin. other potentially effective strategies for recurrent 
cDi include vancomycin with adjunctive treatments, such 
as Saccharomyces boulardii, rifaximin “chaser” therapy after 
vancomycin, nitazoxanide, fecal transplantation, and intravenous 
immunoglobulin. new treatment agents that are active against 
C. difficile, but spare critical components of the normal flora, may 
decrease the incidence of recurrent cDi.18
rifamycins are now being considered for cDAD therapy 
based on in vitro susceptibility data. Hechat et al. reported 
rifampin resistance in three of 110 clinical isolates from the 
United states. the rifampin derivative rifaximin has emerged 
as an attractive potential therapy for cDAD because of its lack 
of systemic absorption. the high levels of rifaximin that can 
be achieved in the gut are an ideal pharmacologic profile for 
cDAD treatment. the rates of spontaneous rifaximin resistance 
based on agar dilution have been reported to be < 10-9 at drug 
concentrations that are eight times the rifaximin Mic for 
C. difficile. successful rifaximin treatment of patients experiencing 
a cDAD relapse has been reported. Exposure to rifamycins before 
the development of cDAD was a risk factor for rifampin-resistant 
cDi. the use of rifaximin may be limited for treatment of cDAD.26 
At the present time, oral bacteria/yeast products do not have 
a role in the prevention or therapy of cDi. Widespread use of 
some products may lead to blood stream infection (bsi) in 
susceptible individuals, and careless use of S. boulardii in an 
intensive care setting may place other patients at risk.27
A notable pattern found in the study by Marya et al. was that 
the regions with the higher incidence of cDAD (northeast and 
Midwest) exhibited higher incidence of VrE in at least half of 
the study period, consistent with the observation that infection 
with cDAD can facilitate transmission of VrE.28,29 this positive 
relationship should be further investigated. the similarity in the 
geographic distribution of ibD and C. difficile colitis could indicate 
the influence of C. difficile colitis in shaping the geographic 
patterns of ibD. it could also indicate that shared environmental 
risk factors influence the occurrence of ibD, as well as C. difficile 
colitis.30 there are several prediction rules. in the rUWA (ratio of 
white cell count on the day of the positive cDt test to two days 
previously, urea, white cell count, and albumin on the day of the 
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positive cDt test) scoring system,31 which is a novel predictive 
tool for the identification of patients at high risk for complications 
from cDi, negative predictive value was high (97.6%). therefore, 
there is only a small chance that a severe case will not be 
identified using the rUWA system. White cell count (Wcc) in 
the first three days is the strongest serum predictor of mortality 
and should be routinely monitored. A Wcc of 20x109/L or greater 
may be the best cutoff value to identify objectively cases at higher 
risk of death.32 Prospective derivation and validation of a clinical 
prediction rule for recurrent C. difficile infection (age, horn index, 
additional antibiotic use, antitoxin A igG < 1.29)33 can be used in 
the future. in this study, relapse, treatment, mortality, outcome, 
and the virulence of the nAP strain, which are the limitations of 
this study, were not investigated. future studies are expected to 
cover these subjects.
Effective prevention measures for C. difficile infection 
include contact isolation, antimicrobial stewardship, and 
proper room cleaning technique. Environmental sampling 
revealed the presence of spores on faecally contaminated 
equipment such as commodes and bedpan shells, which 
persisted after cleaning. cleaning agents for clinical equipment 
must have sporicidal activity to prevent cross-transmission. 
More stringent control measures, including the addition of 
sodium hypochlorite to cleaning solutions and isolation 
of patients are required.34 Diarrhea, when it is the only 
symptom in hospitalized patient should drive physicians 
to rethink about the possibility of cDi, especially in elderly 
patients. the prevalence of asymptomatic C. difficile carriage in 
an irish continuing care institution for the elderly was 10%, 7% 
of which were toxin positive. this highlights the importance of 
increased vigilance for C. difficile using microbial and molecular 
methodology, and identifies patients at increased risk 
following antibiotic administration.35 identifying patients who 
are at high risk for severe cDAD early in the course of their 
infection may help clinicians improve outcomes. by studying 
this disease in different patient populations, researchers may 
uncover unique risk factors and associations, which 
may help to shed light on its pathogenesis. this study reveals 
the importance of evaluating different patient populations 
aiming for better understanding the pathogenesis of disease. 
Prudent use of antibiotics and infection control are strategies 
to prevent cDi in clinical setting. Awareness of cDi is critical to 
provide appropriate clinical care. the surveillance of the 
national incidence rate and multicenter studies are needed, and 
the potential value of a C. difficile vaccine should be studied.36
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